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The emergence of the SARS-CoV-2 virus in Decem-
ber 2019 and the subsequent coronavirus disease 2019 
(COVID-19) pandemic has presented the world with the 
most serious health threat in living memory. The result-
ant pandemic has caused millions of deaths and unprec-
edented social and economic disruption. The response 
to the pandemic has also been unprecedented; countries 
have closed their borders, some have instituted draconian 
but effective public health measures, and the global sci-
entific community has come together to produce robust 
research evidence and novel vaccines in record time. 
Mass vaccination programs are now underway, and while 
it is too early to know clearly their effectiveness in ending 
the pandemic, we can hope that this marks the beginning 
of the end.
The pandemic has put intensive care units, ventila-
tors, vaccines, corticosteroids, and immunotherapies into 
the headlines of print and television news and all forms 
of digital and social media. The progress in response to 
COVID-19 stands in stark contrast to that of intensive 
care practitioners’ signature condition, namely sepsis. 
Sepsis, defined as “life-threatening organ dysfunction 
caused by a dysregulated host response to infection” [1], 
is an umbrella term describing the clinical syndrome 
which can arise from infections caused by bacteria, 
viruses, fungi, and other micro-organisms. Recently, esti-
mates for global, regional, and national sepsis incidence 
and mortality were published by the Global Burden of 
Disease Study [2]. In 2017, sepsis was estimated to affect 
close to 50 million people and to cause or contribute to 
11 million deaths, with over 3 million of those deaths 
being in children or adolescents [2]. Despite these har-
rowing statistics, decades of scientific enquiry, and lit-
erally billions of euros spent on clinical trials, there are 
currently no specific treatments effective for sepsis in 
general. Current efforts to reduce the global burden of 
sepsis are focused on improving public and healthcare 
worker awareness to avoid delays in diagnosis and treat-
ment, and rapid treatment using appropriate antibiotics 
and bundles of supportive care focused on the common 
bacterial causes of sepsis [3].
Patients critically ill with COVID-19 satisfy the diag-
nostic criteria for sepsis and exhibit a phenotype and 
pathology with both similarities and differences to that 
of sepsis caused by other pathogens. Patients with severe 
COVID-19 suffer from multi-organ dysfunction, includ-
ing acute respiratory distress syndrome (ARDS), vaso-
dilatory shock, acute kidney injury, coagulation, brain, 
heart, and gastrointestinal dysfunction, representing 
the common manifestations that characterise sepsis. In 
fact, management guidelines for COVID-19 have been 
directly developed from similar sepsis guidelines [4].
COVID-19-induced sepsis also has features that 
appear unique. While children may develop multi-sys-
tem inflammatory syndrome [5], they rarely suffer from 
severe COVID-19 in marked contrast to other forms of 
sepsis that result in the deaths of over 3 million children 
each year. Childhood deaths from sepsis occur mainly 
in low and middle-income countries, particularly in 
sub-Saharan Africa, and many are due to sepsis in rela-
tion to respiratory infections and diarrhoeal diseases [2]. 
SARS-CoV-2 overwhelmingly causes sepsis from respira-
tory infections whereas, although respiratory infections 
are the commonest cause of fatal non-COVID sepsis, 
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infections at other sites cause a substantial proportion 
of non-COVID sepsis [2]. Other features differentiating 
COVID-19 include direct viral toxicity [6], pulmonary 
vascular injury, and a more marked hypercoagulable state 
[7]. The identification of these features has been made 
possible by the intense study of millions of cases of sepsis 
caused by this one unique and readily identifiable patho-
gen. Similar differentiating features may exist in subsets 
of patients with sepsis due to other individual pathogens 
that have not been subject to the same intense investi-
gation, and which are not readily apparent in studies of 
heterogeneous populations infected with a wide variety 
of sepsis-inducing microorganisms. Another feature of 
COVID-19 to attract attention is the prolonged morbid-
ity beyond the acute illness that has been termed “long 
COVID” [8]. This occurs not only in those who have been 
critically ill but is also reported in patients with much 
milder disease. That patients who survive other forms 
of sepsis suffer similar longer term ill effects is not well 
recognised [9]. Recent studies demonstrate up to 50% of 
sepsis survivors will suffer from a post-sepsis syndrome 
characterized by persisting physical, cognitive and psy-
chological sequelae [9]. This ongoing morbidity repre-
sents an important but poorly quantified component of 
the global burden of sepsis.
In the absence of specific effective treatments, support-
ive therapies for organ dysfunction remain the mainstay 
of the treatment of non-COVID sepsis, and uncertainty 
remains about the safety and efficacy of many widely used 
adjunctive treatments. In contrast, the global research 
effort encompassing basic science and laboratory inves-
tigation together with rapidly-recruiting clinical trials 
has already provided robust evidence for and against the 
use of specific treatments for COVID-related sepsis. The 
demonstrated benefit of corticosteroids in reducing mor-
tality from COVID-19 [10, 11]. stands in stark contrast to 
the investigation of corticosteroids to treat non-COVID 
Sepsis where more than five decades of research and at 
least 40 clinical trials have resulted in equivocal evidence 
of their effectiveness [12].
There are clear, understandable, and justifiable rea-
sons for the global response to COVID-19 being much 
greater than that for endemic sepsis. The virus is eas-
ily and rapidly transmissible causing many millions 
of cases and deaths in a short period of time. This 
has the potential to overwhelm health care systems 
and to cause unprecedented societal and economic 
disruption. Nevertheless, looking toward the control 
of the pandemic is the appropriate time to consider 
how the response to the pandemic can inform efforts 
to substantially reduce the current and future global 
burden of sepsis. One of the most important aspects 
of COVID-19 has been the rapid generation of reliable 
evidence by platform trials, such as REMAP-CAP [13] 
as well as new clinical outcomes targets developed by 
the WHO [14]. Broad acceptance of these newer trial 
designs and outcome targets has facilitated research in 
COVID-19 that may also be applied in sepsis research.
The COVID-19 pandemic has dramatically illustrated 
the crucial role of policymakers in enacting public 
health regulations to control the spread of the virus, 
this success depends not only on close collaboration 
between clinicians but also on effective public messag-
ing to achieve compliance. Public health measures tar-
geted at preventing infection, notably vaccination and 
the provision of clean water and hygienic health care 
have the potential to dramatically reduce the burden of 
sepsis, particularly maternal sepsis and sepsis in chil-
dren in low and middle-income countries. Addition-
ally, policymakers actively supporting the embedding 
of clinical research into routine care, notably in the 
United Kingdom [15], has been crucial in generating 
public trust and engagement in clinical research. These 
are all recommended actions of the 2017 World Health 
Assembly resolution on improving the prevention, 
diagnosis, and clinical management of sepsis [16].
Similar to cancer, sepsis is a valuable overall term that 
could become recognizable to the public. Also similar 
to cancer, sepsis will benefit from more precise molecu-
lar definitions and identifying phenotypes more likely 
to respond to new therapeutics.
Recognising that sepsis results from a dysregulated 
host response to infection and the failure of prior 
research efforts to identify specific treatments, the 
research infrastructure, notably international adap-
tive platform trials, set up or adapted to rapidly inves-
tigate treatments for COVID-19 should be maintained 
and supported beyond the end of the pandemic. With 
an estimated 50 million cases of sepsis occurring each 
year, including even a small proportion of affected 
patients in such trials would allow us to determine 
which patients and which forms of sepsis are amenable 
to treatment with immunomodulators and other treat-
ments, and to investigate how to prevent and treat the 
longer-term health effects of sepsis.
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Planning for post-pandemic sepsis research and pol-
icy should start now. Reducing the global burden of 
sepsis, particularly in resource-poor settings, would be 
a fitting legacy for the tragedy of this global pandemic.
Specific actions based on the pandemic that will 
reduce the global burden of sepsis:
Recognition that sepsis, like cancer, is a valuable umbrella term describ-
ing a heterogeneous syndrome with a core underlying mechanism; a 
dysregulated immune response to infection
Recognition that sepsis caused by different pathogens and in different 
populations may respond to different treatment approaches
Fostering  the understanding that increasing awareness of sepsis, educa-
tion of the public and health care professionals on the prevention, early 
recognition, the need to manage sepsis as an emergency, and good 
training in supportive care will reduce sepsis mortality from all causes
Maintaining political and policymaker focus on public health measures 
that can reduce the global burden of sepsis and by following the 
requests of the WHO sepsis resolution to integrate sepsis in the national 
health strategies of all member states
Supporting with research funding and infrastructure to better under-
stand the overall burden of sepsis and to characterize the heterogene-
ity of sepsis caused by different organisms in different populations and 
expanding the capacity of international platform trials embedded in 
routine clinical care
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